Ratings Embecta Corp.

Equities

EMBC

US29082K1051

Real-time Estimate Cboe BZX Other stock markets 03:32:20 2024-05-28 pm EDT			5-day change	1st Jan Change
13.04 ^USD	-0.69%		-4.64%	-31.04%

May. 16	Transcript : Embecta Corp. Presents at Bank of America Health Care Conference 2024, May-16-2024 10:00 AM
May. 09	Health Care Climbs as Obesity-Drug Optimism Returns - Health Care Roundup	DJ

Summary

On the basis of various fundamental qualitative criteria, the company appears to be particularly poorly ranked from a medium and long-term investment perspective.
Overall, and from a short-term perspective, the company presents an interesting fundamental situation.

Strengths

The company's EBITDA/Sales ratio is relatively high and results in high margins before depreciation, amortization and taxes.
With a P/E ratio at 10.81 for the current year and 7.93 for next year, earnings multiples are highly attractive compared with competitors.
The company is one of the best yield companies with high dividend expectations.
Over the past twelve months, analysts' opinions have been strongly revised upwards.
There is high visibility into the group's activities for the coming years. Outlooks on future revenues from analysts covering the equity remain similar. Such hardly dispersed estimates support highly predictable sales for the current and upcoming fiscal years.

Weaknesses

According to Standard & Poor's' forecast, revenue growth prospects are expected to be very low for the next fiscal years.
The company is in a hindered financial situation with significant debt and rather low EBITDA levels.
For the last 12 months, analysts have been regularly downgrading their EPS expectations. Analysts predict worse results for the company against their predictions a year ago.
Most analysts recommend that the stock should be sold or reduced.
Over the past four months, analysts' average price target has been revised downwards significantly.
The group usually releases earnings worse than estimated.

Ratings chart - Surperformance

Sector: Medical Equipment, Supplies & Distribution

	1st Jan change	Capi.	ESG Refinitiv
EMBECTA CORP.	-30.64%	757M	-
ABBOTT LABORATORIES	-5.56%	181B	C+
MEDTRONIC PLC	-0.11%	108B	C
BECTON, DICKINSON AND COMPANY	-6.17%	66.12B	A
DEXCOM, INC.	+2.64%	50.65B	B-
CENCORA, INC.	+6.58%	43.11B	B-
HOYA CORPORATION	+3.49%	40.74B	B+
METTLER-TOLEDO INTERNATIONAL, INC.	+21.98%	31.6B	B
TERUMO CORPORATION	+16.38%	25.56B	A-
WEST PHARMACEUTICAL SERVICES, INC.	-5.81%	24.16B	A-

Investor Rating

Trading Rating

ESG Refinitiv

Financials

Sales growth

Earnings Growth

EBITDA / Sales

Profitability

Finances

Valuation

P/E ratio

EV / Sales

Price to Book

Price to Free Cash Flow

Yield

Momentum

1 year Revenue revision

4 months Revenue revision

7 days Revenue revision

1 year EPS revision

4 months EPS revision

Consensus

Analyst Opinion

Potential Price Target

4m Target Price Revision

4m Revision of opinion

12m Revision of opinion

Business Predictability

Analyst Coverage

Divergence of Estimates

Divergence of analysts' opinions

Divergence of Target Price

Earnings quality

Technical analysis

ST Timing

MT Timing

LT Timing

RSI

Bollinger Spread

Unusual volumes